Sanofi SA

SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    74,846

Sanofi SA News & Analysis

retirement

The top shares of Australia’s best performing super funds

And our equity analysts’ outlook for the stocks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,424.3013.10-0.14%
CAC 408,714.9315.220.17%
DAX 4026,319.45179.320.69%
Dow JONES (US)54,036.93151.830.28%
FTSE 10010,901.0933.200.31%
HKSE25,880.11212.080.83%
NASDAQ26,690.62342.261.30%
Nikkei 22566,879.121,272.411.94%
NZX 50 Index13,888.2464.110.46%
S&P 5007,757.6447.680.62%
S&P/ASX 2009,233.4016.20-0.18%
SSE Composite Index3,952.5412.500.32%

Market Movers